Abstract
Mitochondrial dysfunction has been described as an early pathological mechanism delineating the selective neurodegeneration that occurs in Huntington’s disease (HD), a polyglutamine-expansion disorder that largely affects the striatum and the cerebral cortex. Over the years, mitochondria roles in eukaryotic cells (e.g. in neurons) have largely diverged from the classically attributed cell power source; indeed, mitochondria not only contribute for synthesis of several metabolites, but are also dynamic organelles that fragment and fuse to achieve a maximal bioenergetic performance, are transported along microtubules, regulate intracellular calcium homeostasis through the interaction with the endoplasmic reticulum, produce free radicals and participate in cell death processes. Indeed, most of these activities have been demonstrated to be affected in HD, potentially contributing for the neuronal dysfunction in pre-symptomatic stages. This chapter resumes some of the evidences that pose mitochondria as a main regulatory organelle in HD-affected neurons, uncovering some potentially therapeutic mitochondrial-based relevant targets.
Access provided by CONRICYT-eBooks. Download chapter PDF
Similar content being viewed by others
Keywords
3.1 Introduction
Mitochondria are double-membrane organelles that represent the major bioenergetic hub coordinating cell and organism homeostasis. Mitochondria control the production of energy (in the form of adenosine triphosphate, ATP) through oxidative phosphorylation (OXPHOS), supporting the biosynthetic and degradative metabolic requirements of the cells, intracellular calcium (Ca2+) homeostasis, apoptotic and cell signaling pathways, among other cellular processes. The sustained integrity of mitochondria is critical for preserving cell viability; therefore, mitochondrial dysfunction is a common process connecting several neurodegenerative and age-related disorders [1], either due to defects in respiratory function, modified organelle dynamics and degradation, cumulating in DNA and protein damage and/or producing excessive amounts of reactive oxygen species (ROS).
Mitochondrial dysfunction plays a major role in the pathogenesis of Huntington’s disease (HD), an autosomal dominant neurodegenerative disorder that initially affects the striatum (mainly the caudate) and later the cortex. HD is characterized by psychiatric disturbances, cognitive deficits, involuntary choreiform movements, dementia and weight loss. All HD cases possess, at least in one of their two copies of the HTT gene, a polymorphic CAG repeat tract expansion that encodes for a N-terminal polyglutamine (polyQ) segment of more than 39 residues in the huntingtin protein (HTT) named mutant HTT (mHTT) [2]. Striatal neurodegeneration linked to mitochondrial deregulation has been demonstrated in genetic and toxin-induced animal and cellular models and post-mortem HD human brain tissue [3, 4]. Of relevance, magnetic resonance spectroscopy revealed impaired ATP synthesis and oxidative function in pre-symptomatic HD carriers [5], suggesting that mitochondrial deficits might initiate disease onset.
In this chapter we discuss the role of mitochondrial deregulation in HD-related neuronal dysfunction and degeneration, particularly focusing on changes in energy metabolism, dynamics and movement and the regulation of apoptosis in both central and peripheral HD humanized cell and animal models, in HD human peripheral cells and post-mortem brain samples, as well as in HD human induced pluripotent stem cells (iPSCs), a powerful model to study HD cellular pathogenesis in a pre-differentiation neural stage of the disease and after differentiation into a striatal-like neuronal fate.
3.2 Mitochondrial Dysfunction in HD
Early evidence of mitochondrial defects in HD came from a study demonstrating ultrastructural abnormalities in mitochondria isolated from post-mortem HD cortical tissue [6]. Additionally, the observation that systemic administration of 3-nitropropionic acid (3-NP, an irreversible mitochondrial complex II inhibitor) in rodents or non-human primates produced preferential degeneration in the caudate–putamen that resembled many behavioral and anatomical features of HD, supported the previous evidence [4, 7, 8]. Defects in complexes II, III and IV activities from HD patients’ striatum were demonstrated simultaneously [9]. A few years later, mHTT was shown to directly interact with the mitochondrial outer membrane (MOM) [10,11,12], triggering Ca2+ release and abnormal mitochondrial morphology and trafficking, as shown in postmortem HD patient’s brain specimens, in human HD lymphoblasts or mice neurons expressing the expanded exon 1 of HTT [12,13,14]. Furthermore, interaction of N-terminal fragments of mHTT with the translocase of the inner membrane TIM23 was shown recently, culminating in the inhibition of protein import machinery and neuronal death. Mitochondria from brain synaptosomes of presymptomatic HD mice also exhibited a protein import defect, but not liver mitochondria, suggesting an early and tissue-specific event of the disease [15]. Considering these observations, this section will focus on reports describing how mHTT may cause mitochondrial dysfunction by either a direct interaction with the organelle and modulation of respiration, mitochondrial membrane potential and Ca2+ buffering and mitochondrial bioenergetics, which further impact on ROS production and oxidative damage.
3.2.1 Altered Mitochondrial Membrane Potential and Impaired Mitochondrial Respiratory Chain Complex Activity
Electron flow along the respiratory complexes I–IV, localized at the mitochondrial inner membrane (MIM), is coupled to proton translocation into the mitochondrial intermembrane space (MIS), creating an electrochemical proton gradient (proton motive force) and thus a mitochondrial transmembrane potential (Δψm) of −150 to −180 mV that drives ATP synthesis. This energy production requires Δψm to be maintained at 80–90% of its maximum value ([16], for review). However, in HD mitochondria this percentage is not preserved. Brain mitochondria isolated from two lines of YAC72 mice expressing “low” and “high” levels of full lenght-mHTT displayed depolarized membrane, with mitochondria from YAC72 high expressor depolarizing faster after Ca2+ stimulation [11]. Similar defect in Δψm was found in mitochondria from chimeric human-mouse mHTT-expressing cells in response to increasing Ca2+ concentrations [17]. Remarkably, a large amount of evidence has shown that HD mitochondria from human lymphoblasts are highly susceptible to decreased Δψm [11, 18], which was correlated with increased glutamine repeats [19], suggesting that the adverse effect of mHTT is not limited to neurons. Indeed, results obtained in our laboratory in symptomatic HD cybrids (an ex vivo peripheral model obtained from the fusion of HD human platelets with mtDNA-depleted rho0 cells) versus control cybrids and in HD human B-lymphocytes evidenced significant changes in Δψm linked to apoptotic events [20, 21]. Interestingly, constitutive HTT phosphorylation at serine 421 completely abrogated the deregulation of Δψm in HD human lymphoblasts [18], linking the neuroprotective effects of HTT phosphorylation in this residue (e.g. [22]) to improved mitochondrial function.
A dramatically decrease in the activity of complex II (succinate dehydrogenase, SDH)/III (cytochrome c reductase) and mildly complex IV (cytochrome c oxidase) in the caudate or putamen were observed in postmortem studies of symptomatic HD patients or HD models, namely immortalized striatal cell lines, animal model brains or human peripheral cells [9, 23, 24, 25, 26, 27], and may contribute for decreased Δψm. Additionally, the decrease in complex II in humans, rodents or primates following administration of 3-NP or malonate (complex II reversible inhibitor) causes HD-like symptoms in animal models and striatal cytotoxicity ([28], for review). Although the selective inhibition of the striatum by a chemical compound such as 3-NP has posed several questions, reduced activity of mitochondrial respiratory chain complexes can largely contribute to accelerate mitochondrial dysfuncton in HD.
3.2.2 Defects in Mitochondrial Ca2+ Handling
The MIM possesses a Ca2+ uniporter (MCU, mitochondrial calcium uniporter), providing cells with a protective high capacity for Ca2+ buffering. Moreover, interaction of mHTT with the MOM may induce the opening of a high conductance pathway, the mitochondrial permeability transition pore (PTP), which is triggered by Ca2+, ROS or decreased adenine nucleotide levels, causing mitochondrial swelling, depolarization and, eventually, cell death [10, 11, 17]. Thus, deficits in mitochondrial Ca2+ handling likely contribute to HD neurodegeneration . Studies performed by Panov and colleagues demonstrated that mitochondria isolated from lymphoblasts of HD patients and from brains of transgenic yeast artificial chromosome (YAC) mice expressing full-length mHTT with 72 glutamines (YAC72) exhibited pronounced defects in Ca2+ handling. Importantly, these defects persisted even in the presence of PTP inhibitors [11]. Impaired mitochondrial Ca2+ homeostasis was also confirmed in intact HD human lymphoblasts following exposure to hydrogen peroxide (H2O2) [18]. Moreover, mitochondria obtained from liver of homozygous knock-in Hdh150/150 mice or treated with recombinant truncated mHTT protein showed augmented predisposition to Ca2+-stimulated PTP induction [10]. Contrariwise, increased Ca2+ uptake was observed in isolated brain non-synaptic mitochondria from R6/2 mice (the most commonly used HD model expressing human HTT exon 1 with ~150 CAG repeats ) and YAC128 HD mice, when compared to mitochondria from wild-type mice [29]. Indeed, two years earlier, Brustovetsky and colleagues had shown that striatal mitochondria from R6/2 exhibited increased resistance to Ca2+, while in striatal mitochondria from littermate controls, lower doses of Ca2+ consistently evoked PTP more easily. Mitochondrial from knock-in HD mice also became more resistant to Ca2+ with increasing age and retained these levels of sensitivity throughout life [30], suggesting that mitochondria are capable of compensatory changes towards neuroprotection. Meanwhile, recent data obtained with isolated brain synaptic and non-synaptic mitochondria from YAC128 mice suggest that increased Ca2+ uptake capacity can be directly correlated with the amount of mHTT associated with the mitochondrial membrane [31]. In addition, HD-iPSC -derived neuronal-like cells expressing both GABA (γ-aminobutyric acid)-A receptor and ionotropic glutamate receptors (obtained from fibroblasts of symptomatic HD patients retaining 60 or 180 CAGs) revealed a clear CAG expansion-dependent decrease in Ca2+ uptake following a chronic glutamate stimulus [32].
3.2.3 Energy Metabolic Deficits
Neurons are highly dependent on mitochondrial ATP production to maintain normal synaptic communication. Therefore, they are very sensitive to disturbed energy metabolism. A number of studies, from HD postmortem brains [33] to transgenic HD mouse brain [34, 35], revealed mHTT-related abnormal ATP/ADP and phosphocreatine/inorganic phosphate (PCr/Pi) ratios and energy charges. This reduction in mitochondrial ATP levels might be linked to increased Ca2+ influx through N-methyl-D-aspartate receptors, since ATP/ADP ratio could be normalized by blocking Ca2+ influx in mHTT-expressing striatal cells [36]. Moreover, a poor creatine kinase (CK)/PCr system in HD brain might also contribute for this reduction [37] (Fig. 3.1). As described before for changes in Δψm, bioenergetic defects in HD are not only confined to the brain, but are also observed in peripheral tissues, such as muscle [5, 38] or lymphoblasts [36]. These findings raise the possibility that the ubiquitous expression of mHTT may place other cell types at risk, particularly those with high metabolic demand. Remarkably, recent studies conducted in our laboratory showed that glucose deprivation did not exacerbate the defects in ATP/ADP ratio in cortical primary cultures derived from YAC128 mice, contrarily to wild-type neurons, pointing to an abnormal glycolytic pathway linked to deficient ATP generation [39]. Studies on mitochondrial oxidative metabolism in presymptomatic and symptomatic HD patients previously detected a selective defect in glycolysis in early HD striatum [40,41,42], suggesting that metabolic deficits in HD may precede neuropathology and clinical symptoms . Indeed, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) has an essential function in glycolysis, binding both normal and mHTT, but with a preferential interaction to cleaved polyQ domain, enhancing nuclear translocation of mHTT and cytotoxicity [43]. Interestingly, studies using an allelic series of murine CAG knock-in embryonic stem cell (ESC) lines have shown dominant CAG-length dependent reduction in energy metabolism [44]. In addition, human derived HD specific neural stem cells showed significantly decreased intracellular ATP [32], supporting the hypothesis that bioenergetic dysfunction is an early event in HD.
Elevated levels of lactate and increased lactate/pyruvate ratio have been also described in striatum , cortex and cerebrospinal fluid from HD patients [45,46,47], as well as in brains from YAC128 and R6/2 transgenic mouse models [34, 48]. Concordantly, we observed that HD cybrid lines exhibited increased lactate/pyruvate levels, which were correlated with a large decrease in the activity and protein levels of pyruvate dehydrogenase (PDH) [49], a protein complex located in the mitochondrial matrix, responsible for catalyzing the irreversible oxidative decarboxylation of pyruvate to acetyl-CoA (Fig. 3.1). Decreased mitochondrial metabolism in caudate (in particular) and putamen of HD patients was previously assessed through a progressive decrement in PDH complex [50, 51], whereas dichloroacetate, a PDH kinase inhibitor previously shown to increase PDH activity, prevented the increase of cerebral lactate concentrations and attenuated the development of striatal neuron atrophy in R6/2 and N171-82Q transgenic HD models [52]. Besides the PDH complex, tricarboxylic acid (TCA) cycle enzymes that provide the main pathway for generating reducing equivalents, such as aconitase, α-ketoglutarate dehydrogenase (α-KGDH) or SDH are also compromised in central HD tissues [53, 54] (Fig. 3.1). Cultured striatal neurons expressing N-terminal HTT fragment showed decreased SDH activity, the only enzyme that participates in both TCA cycle and electron transport chain (ETC) [23]. Contrariwise, in peripheral HD cybrids α-KGDH enzymatic activity was increased [49, 55, 56], suggesting a compensatory mechanism to re-establish NADH levels.
3.3 Oxidative Dysregulation
Under physiological conditions about 1% of O2 consumed generates superoxide anion (O •−2 ) at the mitochondrial respiratory chain due to the leakage of electrons at the level of complexes I and III. Indeed, mitochondria are both sources (at the level of complexes I and III) and targets of ROS, contributing to mitochondrial damage in several pathologies. In complex I (reduced β-nicotinamide adenine dinucleotide (NADH)-ubiquinone:oxidoreductase), flavin mononucleotide (FMN) accepts electrons from NADH passing them through a chain of iron–sulfur centers to the ubiquinone (CoQ, coenzyme Q) reduction site. Complex I-dependent ROS production is influenced by the matrix redox potential (NADH/NAD+ ratio) and is enhanced by its selective inhibitor, rotenone, which prevents the transfer of electrons to the CoQ-binding site [57]. Complex III catalyzes the reduction of cytochrome c by oxidation of CoQ, which has two reaction centers, the ubiquinol-oxidation center (Qo site) and the ubiquinone-reduction center (Qi site). Inhibition of Qi site by antimycin A prompts the production of large amounts of O •−2 on both sides of the MIM [58]. O •−2 is highly membrane impermeable, however it can be readily dismutated to H2O2 by superoxide dismutases (SOD); in contrast, H2O2 diffuses across membranes [59]. Mitochondria have their own antioxidant defense system, thus minimizing the deleterious effects exerted by ROS. The first line of defense involves the dismutation of O •−2 to H2O2 by metal-containing enzymes, comprising Mn-SOD (SOD2), located in the mitochondrial matrix, and Cu,Zn-SOD (SOD1) at the MIS and cytosol. H2O2 can also be effectively detoxified by mitochondrial antioxidant enzymes like glutathione peroxidases (Gpx), which are also present in the cytosol and by peroxiredoxins (Prx) and catalase, the latter located in the peroxisomes, which convert H2O2 into H2O and O2 [60, 61].
The major cause for energetic deficits in HD involves mitochondrial abnormalities and ROS production triggered by mHTT-mitochondria interactions (in a polyQ length-dependent manner), which impair oxidative phosphorylation and ATP production [62]. Aconitase is an iron-sulphur enzyme of the TCA cycle that is particularly susceptible to ROS. Several studies found that it is strongly affected in postmortem human HD caudate, putamen and cortex [55, 63, 64] and in striatum from R6/2 mice [65].
A relationship between inhibition of complexes I and III and enhanced levels of mitochondrial-generated O •−2 was previously confirmed by us in HD striatal cells [66]. Enhanced ROS formation occurring mainly via mitochondria, observed in knock-in striatal cells expressing mHtt (STHdhQ111/Q111), was related with altered activities and levels of antioxidant defense systems, and decreased antioxidant response to exogenous stressors associated to impaired nuclear factor-erythroid 2-related factor-2 (Nrf2) transcriptional activity [66, 67]. An exhaustive proteomic analysis of human HD samples from striatum and cortex showed increased oxidative stress response, defined by the induction of several antioxidant enzymes, namely Prx 1, 2, and 6, and Gpx 1 and 6. Concomitantly, catalase activity was enhanced and SOD2 showed a significant increase of both protein and activity levels in cortex and striatum [63]. Moreover, protein carbonyl formation (a marker of protein oxidation) of glial fibrillary acidic protein, γ-enolase, and CK B was increased in human HD samples from striatum and cortex [63].
Preceding studies in iPSC lines generated from HD patients fibroblasts, ranging from 33 to 180 CAGs, and control fibroblasts, also described increased cell death in HD-iPSC lines in response to toxic stressors, suggesting that HD-iPSCs are increasingly susceptible to ROS [32]. In HD-iPSCs reprogrammed from a juvenile HD patient carrying 72 CAG repeats , Chae and colleagues (2012) shed some light on protein expression profiles that are key regulators of oxidative stress, DNA damage and expression of cytoskeleton associated proteins [68]. These authors found lower levels of SOD1, GST and Gpx1 in HD-iPSC lines, when compared to human embryonic stem cells (hESCs), in contrast with the upregulation of Prx family members, including Prx1, 2 and 6, which have been implicated as important indicators for cellular ROS signals [68].
In summary, mitochondrial dysfunction leads to increased production of ROS, which has a major role in both necrotic and apoptotic mechanisms of cell death (detailed in Sect. 3.6).
3.4 Mitochondrial Biogenesis
Mitochondrial network is constantly being renewed through an equilibrium between biogenesis and degradation of damaged mitochondria (mitophagy ) [69]. Mitochondria biogenesis comprises a multistep process, where mtDNA transcription and translation , along with translation of nuclear-encoded mitochondrial-related transcripts, mitochondrial protein import and overall assembly into a mitochondrial network must proceed correctly [70].
cAMP response element-binding protein (CREB)/TATA-binding protein (TBP)-associated factor (TAF)4 signaling pathway regulates various mitochondrial genes, such as NADH dehydrogenase subunit 5 (ND5) that codes for a subunit of complex I, and is severely disrupted in HD. In fact, mHTT can interact with several transcription factors involved in this pathway, such as CREB-binding protein (CBP) or TAF4/TAFII130 [71, 72]. Ultimately, CREB/TAF4 signaling pathway regulates the expression of peroxisome proliferator-activated receptor γ—PPARγ—coactivator-1α (PGC-1α), one of the major transcriptional regulators of organelle biogenesis [73]. PGC-1α is a major regulator of mitochondrial function, mediating mitochondrial biogenesis and respiration. Being a transcriptional co-activator, it regulates the expression of nuclear-encoded subunits of each of the electron transport-chain complexes, along with genes involved in antioxidant response such as ATP synthase or SOD2 [74]. PGC-1α also regulates nuclear respiratory factor (NRF)1 and 2 and PPAR α, δ and γ by forming heteromeric complexes, sharing a role in the expression of genes such as cytochrome c, complexes I-V and the mitochondrial transcription factor A (Tfam), the major transcriptional regulator of mtDNA [75]. In HD in vitro and in vivo models PGC-1α was found to be repressed, partially due to the direct interaction of mHTT with the signaling pathway mentioned above that regulates its expression, but also by a direct binding to its promoter [73]. HD patients also showed reduced levels of Tfam and PGC-1α as disease severity increases, along with evidences of mitochondrial loss [3, 73, 76, 77] (Fig. 3.2).
3.5 Mitochondrial Dynamics and Mitophagy
Mitochondria are dynamic organelles with frequent changes in size, shape, number and even cellular distribution that directly relate with their function in response to cellular needs or to diverse stimuli [78]. Increasing evidence suggests that unbalanced mitochondrial dynamics take an important role in neurodegeneration in HD ([79] for review). The presence of mHTT appears to reduce the number of mitochondria and leads to their fragmentation, with defects in anterograde and retrograde transport and velocity, ultimately causing neuronal death [80].
3.5.1 Mitochondrial Fission/Fusion Balance
Mitochondria hold the ability to divide (fission) and unite (fusion) in response to diverse stimuli. Both processes allow the exchange of membranes and intramitochondrial content or mobility of the organelle to specific subcellular locations; moreover, fission facilitates apoptosis by regulating the release of MIS proteins into the cytosol, such as cytochrome c [78].
Fission/fusion balance has been reported to be altered in HD, with altered expression of genes involved in these processes, culminating in abnormal mitochondrial morphology and consequently in neuronal dysfunction [81]. Dynamin-related protein 1 (Drp1) takes control of mitochondrial fission. This is a cytosolic protein that can transit towards the MOM upon a fission stimulus, having an effector guanosine triphosphate (GTP)ase domain [82]. Mitochondrial fission 1 (Fis1) and mitochondrial fission factor (Mff), two integral proteins of the MOM, serve as adaptors for Drp1, allowing the recruitment of Drp1 to the effector sites [83]. Meanwhile, fusion counts with machinery of both the MIM and MOM. Mitofusins (Mfn) 1 and 2 are also GTPases, located at the MOM, which are responsible for the fusion of MOMs of the juxtaposing mitochondria. Optic atrophy 1 (OPA1) is the regulator for the MIM fusion process; OPA1 is found at the MIS and shows association with the MIM. Maintenance of Δѱm is required for mitochondrial fusion. As such, after dissipation of Δѱm, fusion is inhibited, but fission can still occur and mitochondrial fragmentation becomes a dominant morphology [84].
A visible decrease in the number of mitochondria in striatal spiny neurons derived from neostriatal tissue of HD patients appears to directly correlate with disease severity [3]. Increased levels of Drp1 and Fis1, along with decreased levels of Mfn1, Mfn2 and OPA1 were found in striatum and cortex of several HD animal models and patients, resulting in excessive mitochondrial fragmentation [80, 85]. In addition to increased expression, interaction of Drp1 with mHTT results in increased GTPase activity [12] (Fig. 3.2), leading to fragmented and less efficient mitochondria that culminates in loss of energy required for neuronal function.
3.5.2 Mitochondrial Trafficking
Impairment in mitochondrial transport along neuronal processes, with slower translocation of the organelle has been associated to HD. Mitochondria trafficking along the cells allows the organelle to be present in subcellular compartments that are in need of a high energy demand. This process is critically important when considering neurons that need energy outside the regular bioenergetic requirements, such as for synaptic transmission. In fact, mHTT-induced fragmented mitochondria are mainly localized in the cell body, not being able to be transported to dendrites, axons or synapses (anterograde movement), which consequently results in low ATP levels at these sites and in overall synaptic degeneration [76].
The processes of mitochondrial fusion and fission can be directly related to their motility. Fission allows for smaller mitochondria to be separated from the rest of the network and to be transported along the microtubules with the aid of dynein, dynactin (retrograde transport) and kinesins motors (anterograde transport) [86]. Mitochondria enlist motor adaptors such as trafficking kinesin protein (TRAK)1 and TRAK2 that bind Miro (MOM protein) to kynesin motors and ensures targeted and precise trafficking in response to neuronal activity [87]. Both N-terminal fragments and full-length mHTT can directly affect mitochondria motility in either anterograde or retrograde movement, resulting in accumulation of the organelle in the soma [76, 88, 89] (Fig. 3.2). Sequestration of mitochondrial transport machinery and blockage by mHTT aggregates may take place, being impossible for mitochondria to move through narrow neuronal projections, as seen in cortical neurons overexpressing mHTT and in HD striatal neurons [89, 90]. Moreover, Orr and colleagues reported altered mitochondrial trafficking in the absence of mHTT aggregates , suggesting an early impairment due to reduced association of mitochondria with motor proteins [76, 88, 89].
3.5.3 Mitophagy
Accumulation of damaged mitochondria occurs in HD cells and can be due to the loss in Δѱm, oxidative stress, impaired OXPHOS, excessive fragmentation and/or decreased biogenesis. Selective mitochondrial degradation by macroautophagy (hereafter termed mitophagy ) ensures mitochondrial quality control and recycling, but must be balanced with biogenesis [91]. Phosphatase and tensin homolog (PTEN)-induced putative kinase 1 (PINK1)/Parkin-dependent mitophagy pathway is the most well characterized mitophagy pathway, although PINK1/Parkin-independent mitophagy can also occur [92, 93]. One example comes from the redistribution of cardiolipin, naturally in the MIM, to the MOM, signaling damaged mitochondria from neuronal cells to undergo degradation. This allows cardiolipin to interact with autophagosome-associated light chain 3 (LC3) [94].
PINK1 is a serine/threonine kinase that localizes in the cytosol and is normally imported into MIM where it is degraded by mitochondrial proteases [95,96,97]. In the presence of damaged mitochondria exhibiting decreased Δѱm, PINK1 is stabilized at the MOM, inducing Parkin translocation to mitochondria [98]. Since Parkin is an E3 ubiquitin ligase, it ligates ubiquitin chains on MOM proteins that are recognized by autophagy adaptors such as p 62 [99]. Khalil and colleagues reported a protective role for PINK1 overexpression in HD flies and STHdhQ111/Q111 cells [100]. Nevertheless, the significance of alterations in PINK1/Parkin-dependent mitophagy has remained elusive in HD.
HTT was proposed to have a role in the control of autophagosome dynamics, along with huntingtin -associated protein 1 (HAP1), through the regulation of dynein and kinesin. Moreover, axonal transport of autophagosomes was found to be impaired in the presence of mHTT. It ultimately ended in inefficient degradation of internalized mitochondria, probably due to inhibition of autophagosome/lysosome fusion [101]. Additionally, wild-type HTT may serve as a scaffold protein in selective autophagy (not just mitophagy ), aiding autophagic adaptor p 62 to associate with LC3 and lysine 63 (K63)-linked ubiquitinated substrates [102]. PolyQ-expanded HTT may thus impede this scaffold function (Fig. 3.2). Indeed, expression of a mHTT transgene in a mice expressing mitochondria-targeted Keima, a protein exhibiting pH-dependent excitation, reduced the levels of mitophagy [103].
3.6 Mitochondrial-Dependent Apoptosis
Intrinsic apoptosis is triggered following the loss of integrity of the MOM, which allows the release of pro-apoptotic factors to the cytosol. The release of proteins such as cytochrome c and Smac/DIABLO (second mitochondria derived activator of caspase/direct inhibitor of apoptosis-binding protein with low pI) induces the formation of the apoptosome. After release from the MIS, cytochrome c forms a complex with deoxy-ATP, Apaf-1 (apoptotic protease-activating factor 1) and the initiator caspase 9, which when activated further activates the executioner caspases (3, 6 and 7) and induces the well-recognized nuclear apoptotic features, such as DNA fragmentation and chromatin condensation [104,105,106]. In neurons, p 53 has also been implicated in upregulating the pro-apoptotic proteins Bax and the BH3-only proteins PUMA (p 53 upregulated modulator of apoptosis) and Noxa [107].
Different evidences reinforce the deleterious influence of mHTT in the apoptotic pathway, particularly by activating several BH3-only proteins. Changes in Bcl-2 (B-cell lymphoma 2), an anti-apoptotic protein, in HD are controversial. In several cell lines with endogenous expression of mHTT or induced to overexpress mHTT, Bcl-2 family protein dysregulation was common; several studies showed decreased Bcl-2 protein and mRNA levels, Bax activation and translocation from the cytosol to mitochondria, followed by Bim (Bcl-2 interacting mediator of cell death) activation [108,109,110,111,112] (Fig. 3.3). However, in animal models of HD, the results are largely controversial, particularly when considering the anti-apoptotic proteins. Initial studies showed that Bcl-2 protein levels were unchanged in total brain or in mitochondrial fractions from R6/1 and R6/2 mice [113,114,115]. Conversely, other studies reported down-regulation of Bcl-2 levels in R6/2 mouse brain [109, 116] and in striatal tissue from N171-82Q mice [108]. Importantly, overexpression of Bcl-2 was shown to slow the disease progression [117]. For other pro-survival proteins, such as Bcl-XL, no major differences were found in total brain and striatum lysates or mitochondrial fractions of R6/1 (control and with low levels of the neurotrophin brain derived neurotrophic factor, BDNF), HD94 (tetracycline inducible expression of mHtt) and R6/2 mouse models [113, 117]. Moreover, higher Smac/DIABLO levels were found in the cytosol of cells overexpressing mHTT and this release was responsible for the degradation of anti-apoptotic IAP1 (Inhibitor of apoptosis protein-1) and XIAP (X-linked inhibitor of apoptosis) proteins in the cytosol of HD striatal cells [118]. The mitochondrial levels of AIF (apoptosis inducing factor), which induces apoptotic cell death through a caspase-independent pathway, were also found to be reduced in HD mouse striatal cells [119].
More consistent data has been observed in pro-apoptotic proteins examined in HD animal models and patient samples. In mitochondrial brain fractions of R6/1 and R6/2 mice the pro-apoptotic protein Bax was increased; moreover, increased Bax mRNA was described in the cortex and cerebellum of R6/1 mice [113, 115, 117]. A decrease in phosphorylated Bad and activation of caspases-1 and -3 was also reported in R6/2 mice models [117]. In caudate samples from HD patients neostriatal neurodegeneration was associated with enhanced Bax levels, weak caspase-3 immunostaining and cells exhibiting apoptotic morphology, in comparison with controls without neurological disease [120]. These changes seem not to be specific for HD human brain, since increased Bax levels were also described in peripheral B and T lymphocytes and monocytes derived from symptomatic HD patients [20] (Fig. 3.3). Moreover, untreated HD human cybrid lines showed increased mitochondrial Bim and Bak levels, and a slight release in cytochrome c, evidencing their increased susceptibility to intrinsic apoptosis [21]. Another mitochondrial localized BH3-only protein implicated in HD is BNIP3; when activated, BNIP3 causes loss in Δψm and induces mitochondrial fragmentation prior to mitophagy [112]. Although the molecular mechanisms for BNIP3 activation are not well understood, BNIP3 levels were described to be increased in total lysates of HD myoblasts [121].
Numerous studies in vitro and in vivo support the interaction between caspases and HTT in vulnerable cell types in the striatum and cortex leading to increase cell death [122,123,124,125]. Increased expression of caspase-2 was correlated with decreased BDNF levels in the cortex and striatum of YAC72 mice. Htt can be recruited and cleaved by initiator caspase-2, which induces neuritic degeneration. The generated N-terminal toxic fragment was shown to associate with synaptic vesicles and inhibit glutamate uptake. Caspase-7, which is specifically expressed in medium-sized neurons and enriched in the striatum , may also associate with Htt, triggering the activity of other caspases, namely caspase-6, and accelerating the production of Htt fragments and the induction of apoptosis [122, 124]. Two active caspase-3 sites and one caspase-6 site have been largely studied in HTT. Caspase 6 cleavage at the 586 cysteine residue of Htt, but not caspase 3 cleavage, was shown to be required for the development of the characteristic behavioral and neuropathological features of HD [123, 126, 127]. However, recent studies showed that the cleavage pattern was unaltered when mHtt expressing mice were crossed onto caspase knockout background [128, 129], raising the question of whether other caspases might be involved in the generation of cytotoxic mHTT fragments.
3.7 Concluding Remarks
In conclusion, numerous studies have shed some light on the role of mitochondria in the regulatory mechanism of biochemical/molecular functions involved in HD pathophysiology. Increasing evidence support the contribution of mitochondria and oxidative phosphorylation defects in HD patients and cellular and animal HD models as a trigger event for the irreversible cascade of events involved in disease phenotype, as demonstrated by some of the most relevant publications that were generated in this field since 1978 until 2015 (Fig. 3.4). However, many questions remain to be answered regarding the role of mitochondria dysfunction in HD and its influence on other pathological processes and thus on disease progression. The full understanding of how mHTT targets mitochondria leading to a dysfunctional organelle can be foreseen an important advance to identify new molecular pathways and eventually therapeutic targets. So far, few clinical trials aimed to directly improve mitochondrial function in HD, although the results have not been very promising. A study concerning coenzyme Q10 intake was canceled at phase III due to the lack of results. Other bioenergetic agents tested include creatine and cysteamine bitartrate, the latter the neuroactive metabolite of cystamine. The present chapter clearly points out several molecular changes that can be the targets of more efficient mitochondrial-based therapies and may impact on the organelle physiology. Considering the diversity of changes operated just in a single organelle such as mitochondria, development of combined therapies aiming to improve these alterations may help to delay HD onset and/or disease progression.
Abbreviations
- Δψm:
-
Mitochondrial membrane potential
- α-KGDH:
-
α-ketoglutarate dehydrogenase
- 3-NP:
-
3-nitropropionic acid
- AIF:
-
Apoptosis inducing factor
- Apaf-1:
-
Apoptotic protease-activating factor 1
- ATP:
-
Adenosine triphosphate
- Bcl-2:
-
B-cell lymphoma 2
- BDNF:
-
Brain derived neurotrophic factor
- BH3:
-
Bcl-2 homology 3
- Bid:
-
BH3 interacting-domain death agonist
- Bim:
-
Bcl-2 interacting mediator of cell death
- BNIP3:
-
BCL2/adenovirus E1B 19 kDa protein-interacting protein 3
- CBP:
-
CREB-binding protein
- CK:
-
Creatine kinase
- CoQ:
-
Coenzyme Q
- CREB:
-
cAMP response element-binding protein
- Drp1:
-
Dynamin-related protein 1
- ETC:
-
Electron transport chain
- Fis1:
-
Mitochondrial fission 1
- FMN:
-
Flavin mononucleotide
- GABA:
-
γ-aminobutyric acid
- GAPDH:
-
Glyceraldehyde-3-phosphate dehydrogenase
- Gpx:
-
Glutathione peroxidases
- GTP:
-
Guanosine triphosphate
- H2O2:
-
Hydrogen peroxide
- HD:
-
Huntington’s disease
- hESC:
-
Human embryonic stem cells
- HTT/HTT:
-
Human huntingtin protein/gene
- Htt:
-
Rodent huntingtin protein
- IAP1:
-
Inhibitor of Apoptosis Protein-1
- iPSCs:
-
Induced pluripotent stem cells
- K:
-
Lysine
- LC3:
-
Light chain 3
- MCU:
-
Mitochondrial calcium uniporter
- Mff:
-
Mitochondrial fission factor
- Mfn:
-
Mitofusin
- mHTT:
-
Human mutant HTT
- mHtt:
-
Rodent mutant Htt
- MIM:
-
Mitochondrial inner membrane
- MIS:
-
Mitochondrial intermembrane space
- MOM:
-
Mitochondrial outer membrane
- mtDNA:
-
Mitochondrial DNA
- NAD:
-
β-nicotinamide adenine dinucleotide
- ND5:
-
NADH dehydrogenase subunit 5
- NRF:
-
Nuclear respiratory factor
- Nrf2:
-
Nuclear factor-erythroid 2-related factor-2
- OPA1:
-
Optic atrophy 1
- OXPHOS:
-
Oxidative phosphorylation
- PCr:
-
Phosphocreatine
- PDH:
-
Pyruvate dehydrogenase
- PGC-1α:
-
PPARγ—coactivator-1α
- PINK1:
-
PTEN-induced putative kinase 1
- PolyQ:
-
Polyglutamine
- PPAR:
-
Peroxisome proliferator-activated receptor
- Prx:
-
Peroxiredoxins
- PTEN:
-
Phosphatase and tensin homolog
- PTP:
-
Permeability transition pore
- PUMA:
-
p 53 upregulated modulator of apoptosis
- ROS:
-
Reactive oxygen species
- SDH:
-
Succinate dehydrogenase
- Smac/DIABLO:
-
Second mitochondria derived activator of caspase/direct inhibitor of apoptosis-binding protein with low pI
- SOD:
-
Superoxide dismutase
- TAF:
-
TBP-associated factor 4
- TBP:
-
TATA-binding protein
- TCA:
-
Tricarboxylic acid
- Tfam:
-
Mitochondrial transcription factor A
- TIM:
-
Translocase of the inner membrane
- TRAK:
-
Trafficking kinesin protein
- XIAP:
-
X-linked inhibitor of apoptosis
- YAC:
-
Yeast artificial chromosome
References
Chaturvedi RK, Flint Beal M (2013) Mitochondrial diseases of the brain. Free Radic Biol Med 63:1–29
Collaborative THsD (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. The Huntington’s Disease Collaborative Research Group. In Cell 971–983
Kim J, Moody JP, Edgerly CK, Bordiuk OL, Cormier K, Smith K, Beal MF, Ferrante RJ (2010) Mitochondrial loss, dysfunction and altered dynamics in Huntington’s disease. Hum Mol Genet 19:3919–3935
Kodsi MH, Swerdlow NR (1997) Mitochondrial toxin 3-nitropropionic acid produces startle reflex abnormalities and striatal damage in rats that model some features of Huntington’s disease. Neurosci Lett 231:103–107
Saft C, Zange J, Andrich J, Muller K, Lindenberg K, Landwehrmeyer B, Vorgerd M, Kraus PH, Przuntek H, Schols L (2005) Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington’s disease. Mov Disord Off J Mov Disord Soc 20:674–679
Goebel HH, Heipertz R, Scholz W, Iqbal K, Tellez-Nagel I (1978) Juvenile Huntington chorea: clinical, ultrastructural, and biochemical studies. Neurology 28:23–31
Beal MF, Brouillet E, Jenkins BG, Ferrante RJ, Kowall NW, Miller JM, Storey E, Srivastava R, Rosen BR, Hyman BT (1993) Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci Off J Soc Neurosci 13:4181–4192
Brouillet E, Hantraye P, Ferrante RJ, Dolan R, Leroy-Willig A, Kowall NW, Beal MF (1995) Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc Natl Acad Sci USA 92:7105–7109
Gu M, Gash MT, Mann VM, Javoy-Agid F, Cooper JM, Schapira AH (1996) Mitochondrial defect in Huntington’s disease caudate nucleus. Ann Neurol 39:385–389
Choo YS, Johnson GV, MacDonald M, Detloff PJ, Lesort M (2004) Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum Mol Genet 13:1407–1420
Panov AV, Gutekunst CA, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ, Greenamyre JT (2002) Early mitochondrial calcium defects in Huntington’s disease are a direct effect of polyglutamines. Nat Neurosci 5:731–736
Song W, Chen J, Petrilli A, Liot G, Klinglmayr E, Zhou Y, Poquiz P, Tjong J, Pouladi MA, Hayden MR et al (2011) Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity. Nat Med 17:377–382
Napoli E, Wong S, Hung C, Ross-Inta C, Bomdica P, Giulivi C (2013) Defective mitochondrial disulfide relay system, altered mitochondrial morphology and function in Huntington’s disease. Hum Mol Genet 22:989–1004
Squitieri F, Cannella M, Sgarbi G, Maglione V, Falleni A, Lenzi P, Baracca A, Cislaghi G, Saft C, Ragona G et al (2006) Severe ultrastructural mitochondrial changes in lymphoblasts homozygous for Huntington disease mutation. Mech Ageing Dev 127:217–220
Yano H, Baranov SV, Baranova OV, Kim J, Pan Y, Yablonska S, Carlisle DL, Ferrante RJ, Kim AH, Friedlander RM (2014) Inhibition of mitochondrial protein import by mutant huntingtin. Nat Neurosci 17:822–831
Nicholls DG, Ward MW (2000) Mitochondrial membrane potential and neuronal glutamate excitotoxicity: mortality and millivolts. Trends Neurosci 23(4):166–174
Milakovic T, Quintanilla RA, Johnson GV (2006) Mutant huntingtin expression induces mitochondrial calcium handling defects in clonal striatal cells: functional consequences. J Biol Chem 281:34785–34795
Naia L, Ferreira IL, Cunha-Oliveira T, Duarte AI, Ribeiro M, Rosenstock TR, Laco MN, Ribeiro MJ, Oliveira CR, Saudou F et al (2015) Activation of IGF-1 and insulin signaling pathways ameliorate mitochondrial function and energy metabolism in Huntington’s Disease human lymphoblasts. Mol Neurobiol 51:331–348
Sawa A, Wiegand GW, Cooper J, Margolis RL, Sharp AH, Lawler JF Jr, Greenamyre JT, Snyder SH, Ross CA (1999) Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nat Med 5:1194–1198
Almeida S, Sarmento-Ribeiro AB, Januario C, Rego AC, Oliveira CR (2008) Evidence of apoptosis and mitochondrial abnormalities in peripheral blood cells of Huntington’s disease patients. Biochem Biophys Res Commun 374:599–603
Ferreira IL, Nascimento MV, Ribeiro M, Almeida S, Cardoso SM, Grazina M, Pratas J, Santos MJ, Januario C, Oliveira CR et al (2010) Mitochondrial-dependent apoptosis in Huntington’s disease human cybrids. Exp Neurol 222:243–255
Humbert S, Bryson EA, Cordelieres FP, Connors NC, Datta SR, Finkbeiner S, Greenberg ME, Saudou F (2002) The IGF-1/Akt pathway is neuroprotective in Huntington’s disease and involves Huntingtin phosphorylation by Akt. Dev Cell 2:831–837
Benchoua A, Trioulier Y, Zala D, Gaillard MC, Lefort N, Dufour N, Saudou F, Elalouf JM, Hirsch E, Hantraye P et al (2006) Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin. Mol Biol Cell 17:1652–1663
Browne SE (2008) Mitochondria and Huntington’s disease pathogenesis: insight from genetic and chemical models. Ann N Y Acad Sci 1147:358–382
Maksimovic ID, Jovanovic MD, Colic M, Mihajlovic R, Micic D, Selakovic V, Ninkovic M, Malicevic Z, Rusic-Stojiljkovic M, Jovicic A (2001) Oxidative damage and metabolic dysfunction in experimental Huntington’s disease: selective vulnerability of the striatum and hippocampus. Vojnosanit Pregl 58:237–242
Pandey M, Varghese M, Sindhu KM, Sreetama S, Navneet AK, Mohanakumar KP, Usha R (2008) Mitochondrial NAD + -linked State 3 respiration and complex-I activity are compromised in the cerebral cortex of 3-nitropropionic acid-induced rat model of Huntington’s disease. J Neurochem 104:420–434
Silva AC, Almeida S, Laco M, Duarte AI, Domingues J, Oliveira CR, Januario C, Rego AC (2013) Mitochondrial respiratory chain complex activity and bioenergetic alterations in human platelets derived from pre-symptomatic and symptomatic Huntington’s disease carriers. Mitochondrion 13:801–809
Chakraborty J, Rajamma U, Mohanakumar KP (2014) A mitochondrial basis for Huntington’s disease: therapeutic prospects. Mol Cell Biochem 389:277–291
Oliveira JM, Jekabsons MB, Chen S, Lin A, Rego AC, Goncalves J, Ellerby LM, Nicholls DG (2007) Mitochondrial dysfunction in Huntington’s disease: the bioenergetics of isolated and in situ mitochondria from transgenic mice. J Neurochem 101:241–249
Brustovetsky N, LaFrance R, Purl KJ, Brustovetsky T, Keene CD, Low WC, Dubinsky JM (2005) Age-dependent changes in the calcium sensitivity of striatal mitochondria in mouse models of Huntington’s Disease. J Neurochem 93:1361–1370
Pellman JJ, Hamilton J, Brustovetsky T, Brustovetsky N (2015) Ca(2+) handling in isolated brain mitochondria and cultured neurons derived from the YAC128 mouse model of Huntington’s disease. J Neurochem 134:652–667
HD iPSC Consortium (2012) Induced pluripotent stem cells from patients with Huntington’s disease show CAG-repeat-expansion-associated phenotypes. Cell stem cell 11:264–278
Mochel F, N’Guyen TM, Deelchand D, Rinaldi D, Valabregue R, Wary C, Carlier PG, Durr A, Henry PG (2012) Abnormal response to cortical activation in early stages of Huntington disease. Movement disorders: official journal of the Movement Disorder Society 27:907–910
Lopes C, Ribeiro M, Duarte AI, Humbert S, Saudou F, Pereira de Almeida L, Hayden M, Rego AC (2014) IGF-1 intranasal administration rescues Huntington’s disease phenotypes in YAC128 mice. Mol Neurobiol 49:1126–1142
Mochel F, Durant B, Meng X, O’Callaghan J, Yu H, Brouillet E, Wheeler VC, Humbert S, Schiffmann R, Durr A (2012) Early alterations of brain cellular energy homeostasis in Huntington disease models. J Biol Chem 287:1361–1370
Seong IS, Ivanova E, Lee JM, Choo YS, Fossale E, Anderson M, Gusella JF, Laramie JM, Myers RH, Lesort M et al (2005) HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. Hum Mol Genet 14:2871–2880
Zhang SF, Hennessey T, Yang L, Starkova NN, Beal MF, Starkov AA (2011) Impaired brain creatine kinase activity in Huntington’s disease. Neurodegener Dis 8:194–201
Lodi R, Schapira AH, Manners D, Styles P, Wood NW, Taylor DJ, Warner TT (2000) Abnormal in vivo skeletal muscle energy metabolism in Huntington’s disease and dentatorubropallidoluysian atrophy. Ann Neurol 48:72–76
Naia L, Ribeiro M, Rodrigues J, Duarte AI, Lopes C, Rosenstock TR, Hayden MR, Rego AC (2016) Insulin and IGF-1 regularize energy metabolites in neural cells expressing full-length mutant huntingtin. Neuropeptides
Antonini A, Leenders KL, Spiegel R, Meier D, Vontobel P, Weigell-Weber M, Sanchez-Pernaute R, de Yebenez JG, Boesiger P, Weindl A et al (1996) Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington’s disease. Brain A J Neurol 119(Pt 6):2085–2095
Mazziotta JC, Phelps ME, Pahl JJ, Huang SC, Baxter LR, Riege WH, Hoffman JM, Kuhl DE, Lanto AB, Wapenski JA et al (1987) Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington’s disease. The New England journal of medicine 316:357–362
Powers WJ, Haas RH, Le T, Videen TO, Hershey T, McGee-Minnich L, Perlmutter JS (2007) Normal platelet mitochondrial complex I activity in Huntington’s disease. Neurobiology of disease 27:99–101
Burke JR, Enghild JJ, Martin ME, Jou YS, Myers RM, Roses AD, Vance JM, Strittmatter WJ (1996) Huntingtin and DRPLA proteins selectively interact with the enzyme GAPDH. Nat Med 2:347–350
Jacobsen JC, Gregory GC, Woda JM, Thompson MN, Coser KR, Murthy V, Kohane IS, Gusella JF, Seong IS, MacDonald ME et al (2011) HD CAG-correlated gene expression changes support a simple dominant gain of function. Hum Mol Genet 20:2846–2860
Jenkins BG, Koroshetz WJ, Beal MF, Rosen BR (1993) Evidence for impairment of energy metabolism in vivo in Huntington’s disease using localized 1H NMR spectroscopy. Neurology 43:2689–2695
Koroshetz WJ, Jenkins BG, Rosen BR, Beal MF (1997) Energy metabolism defects in Huntington’s disease and effects of coenzyme Q10. Ann Neurol 41:160–165
Martin WR, Wieler M, Hanstock CC (2007) Is brain lactate increased in Huntington’s disease? J Neurol Sci 263:70–74
Tsang TM, Woodman B, McLoughlin GA, Griffin JL, Tabrizi SJ, Bates GP, Holmes E (2006) Metabolic characterization of the R6/2 transgenic mouse model of Huntington’s disease by high-resolution MAS 1H NMR spectroscopy. J Proteome Res 5:483–492
Ferreira IL, Cunha-Oliveira T, Nascimento MV, Ribeiro M, Proenca MT, Januario C, Oliveira CR, Rego AC (2011) Bioenergetic dysfunction in Huntington’s disease human cybrids. Exp Neurol 231:127–134
Butterworth J, Yates CM, Reynolds GP (1985) Distribution of phosphate-activated glutaminase, succinic dehydrogenase, pyruvate dehydrogenase and gamma-glutamyl transpeptidase in post-mortem brain from Huntington’s disease and agonal cases. J Neurol Sci 67:161–171
Sorbi S, Bird ED, Blass JP (1983) Decreased pyruvate dehydrogenase complex activity in Huntington and Alzheimer brain. Ann Neurol 13:72–78
Andreassen OA, Ferrante RJ, Huang HM, Dedeoglu A, Park L, Ferrante KL, Kwon J, Borchelt DR, Ross CA, Gibson GE et al (2001) Dichloroacetate exerts therapeutic effects in transgenic mouse models of Huntington’s disease. Ann Neurol 50:112–117
Klivenyi P, Starkov AA, Calingasan NY, Gardian G, Browne SE, Yang L, Bubber P, Gibson GE, Patel MS, Beal MF (2004) Mice deficient in dihydrolipoamide dehydrogenase show increased vulnerability to MPTP, malonate and 3-nitropropionic acid neurotoxicity. J Neurochem 88:1352–1360
Tabrizi SJ, Cleeter MW, Xuereb J, Taanman JW, Cooper JM, Schapira AH (1999) Biochemical abnormalities and excitotoxicity in Huntington’s disease brain. Ann Neurol 45:25–32
Naseri NN, Xu H, Bonica J, Vonsattel JP, Cortes EP, Park LC, Arjomand J, Gibson GE (2015) Abnormalities in the tricarboxylic Acid cycle in Huntington disease and in a Huntington disease mouse model. J Neuropathol Exp Neurol 74:527–537
Sorolla MA, Rodriguez-Colman MJ, Tamarit J, Ortega Z, Lucas JJ, Ferrer I, Ros J, Cabiscol E (2010) Protein oxidation in Huntington disease affects energy production and vitamin B6 metabolism. Free Radic Biol Med 49:612–621
Vinogradov AD, Grivennikova VG (2015) Oxidation of NADH and ROS production by respiratory complex I. Biochim Biophys Acta
Bleier L, Drose S (2013) Superoxide generation by complex III: from mechanistic rationales to functional consequences. Biochim Biophys Acta 1827:1320–1331
Murphy MP (2009) How mitochondria produce reactive oxygen species. Biochem J 417:1–13
Flynn JM, Melov S (2013) SOD2 in mitochondrial dysfunction and neurodegeneration. Free Radic Biol Med 62:4–12
Rabilloud T, Heller M, Rigobello MP, Bindoli A, Aebersold R, Lunardi J (2001) The mitochondrial antioxidant defence system and its response to oxidative stress. Proteomics 1:1105–1110
Hands S, Sajjad MU, Newton MJ, Wyttenbach A (2011) In vitro and in vivo aggregation of a fragment of huntingtin protein directly causes free radical production. J Biol Chem 286:44512–44520
Sorolla MA, Reverter-Branchat G, Tamarit J, Ferrer I, Ros J, Cabiscol E (2008) Proteomic and oxidative stress analysis in human brain samples of Huntington disease. Free Radic Biol Med 45:667–678
Tabrizi SJ, Schapira AH (1999) Secondary abnormalities of mitochondrial DNA associated with neurodegeneration. Biochem Soc Symp 66:99–110
Tabrizi SJ, Workman J, Hart PE, Mangiarini L, Mahal A, Bates G, Cooper JM, Schapira AH (2000) Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse. Ann Neurol 47:80–86
Ribeiro M, Rosenstock TR, Oliveira AM, Oliveira CR, Rego AC (2014) Insulin and IGF-1 improve mitochondrial function in a PI-3 K/Akt-dependent manner and reduce mitochondrial generation of reactive oxygen species in Huntington’s disease knock-in striatal cells. Free Radic Biol Med 74:129–144
Ribeiro M, Rosenstock TR, Cunha-Oliveira T, Ferreira IL, Oliveira CR, Rego AC (2012) Glutathione redox cycle dysregulation in Huntington’s disease knock-in striatal cells. Free Radic Biol Med 53:1857–1867
Chae JI, Kim DW, Lee N, Jeon YJ, Jeon I, Kwon J, Kim J, Soh Y, Lee DS, Seo KS et al (2012) Quantitative proteomic analysis of induced pluripotent stem cells derived from a human Huntington’s disease patient. Biochem J 446:359–371
Stotland A, Gottlieb RA (2015) Mitochondrial quality control: easy come, easy go. Biochim Biophys Acta 1853:2802–2811
Zhu J, Wang KZ, Chu CT (2013) After the banquet: mitochondrial biogenesis, mitophagy, and cell survival. Autophagy 9:1663–1676
Jin YN, Johnson GV (2010) The interrelationship between mitochondrial dysfunction and transcriptional dysregulation in Huntington disease. J Bioenerg Biomembr 42:199–205
Steffan JS, Kazantsev A, Spasic-Boskovic O, Greenwald M, Zhu YZ, Gohler H, Wanker EE, Bates GP, Housman DE, Thompson LM (2000) The Huntington’s disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci USA 97:6763–6768
Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, Krainc D (2006) Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 127:59–69
Johri A, Chandra A, Beal MF (2013) PGC-1alpha, mitochondrial dysfunction, and Huntington’s disease. Free Radic Biol Med 62:37–46
Palikaras K, Tavernarakis N (2014) Mitochondrial homeostasis: the interplay between mitophagy and mitochondrial biogenesis. Exp Gerontol 56:182–188
Shirendeb UP, Calkins MJ, Manczak M, Anekonda V, Dufour B, McBride JL, Mao P, Reddy PH (2012) Mutant huntingtin’s interaction with mitochondrial protein Drp1 impairs mitochondrial biogenesis and causes defective axonal transport and synaptic degeneration in Huntington’s disease. Hum Mol Genet 21:406–420
Weydt P, Pineda VV, Torrence AE, Libby RT, Satterfield TF, Lazarowski ER, Gilbert ML, Morton GJ, Bammler TK, Strand AD et al (2006) Thermoregulatory and metabolic defects in Huntington’s disease transgenic mice implicate PGC-1alpha in Huntington’s disease neurodegeneration. Cell Metab 4:349–362
Detmer SA, Chan DC (2007) Functions and dysfunctions of mitochondrial dynamics. Nat Rev Mol Cell Biol 8:870–879
Rosenstock TR, Brett AC, Rego AC (2012) Modified mitochondrial dynamics, turnover and function in neurodegeneration: a focus on Huntington’s Disease. Cell Bioenerg Health Dis New Perspect Mitochondrial Biol, 149–194
Shirendeb U, Reddy AP, Manczak M, Calkins MJ, Mao P, Tagle DA, Reddy PH (2011) Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington’s disease: implications for selective neuronal damage. Hum Mol Genet 20:1438–1455
Reddy PH, Shirendeb UP (2012) Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington’s disease. Biochim Biophys Acta 1822:101–110
Knott AB, Perkins G, Schwarzenbacher R, Bossy-Wetzel E (2008) Mitochondrial fragmentation in neurodegeneration. Nat Rev Neurosci 9:505–518
Loson OC, Song Z, Chen H, Chan DC (2013) Fis1, Mff, MiD49, and MiD51 mediate Drp1 recruitment in mitochondrial fission. Mol Biol Cell 24(5):659–667
Griffin EE, Detmer SA, Chan DC (2006) Molecular mechanism of mitochondrial membrane fusion. Biochim Biophys Acta 1763:482–489
Costa V, Giacomello M, Hudec R, Lopreiato R, Ermak G, Lim D, Malorni W, Davies KJ, Carafoli E, Scorrano L (2010) Mitochondrial fission and cristae disruption increase the response of cell models of Huntington’s disease to apoptotic stimuli. EMBO Mol Med 2:490–503
Zinsmaier KE, Babic M, Russo GJ (2009) Mitochondrial transport dynamics in axons and dendrites. Results Probl Cell Differ 48:107–139
Lin MY, Sheng ZH (2015) Regulation of mitochondrial transport in neurons. Exp Cell Res 334:35–44
Orr AL, Li S, Wang CE, Li H, Wang J, Rong J, Xu X, Mastroberardino PG, Greenamyre JT, Li XJ (2008) N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. J Neurosci Off J Soc Neurosci 28:2783–2792
Trushina E, Dyer RB, Badger JD 2nd, Ure D, Eide L, Tran DD, Vrieze BT, Legendre-Guillemin V, McPherson PS, Mandavilli BS et al (2004) Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. Mol Cell Biol 24:8195–8209
Chang TWD, Rintoul GL, Pandipati S, Reynolds IJ (2006) Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons. Neurobiol Dis 22(2):388–400
Twig G, Shirihai OS (2011) The interplay between mitochondrial dynamics and mitophagy. Antioxid Redox Signal 14:1939–1951
Allen GF, Toth R, James J, Ganley IG (2013) Loss of iron triggers PINK1/Parkin-independent mitophagy. EMBO Rep 14:1127–1135
Strappazzon F, Nazio F, Corrado M, Cianfanelli V, Romagnoli A, Fimia GM, Campello S, Nardacci R, Piacentini M, Campanella M et al (2015) AMBRA1 is able to induce mitophagy via LC3 binding, regardless of PARKIN and p62/SQSTM1. Cell Death Differ 22:517
Chu CT, Ji J, Dagda RK, Jiang JF, Tyurina YY, Kapralov AA, Tyurin VA, Yanamala N, Shrivastava IH, Mohammadyani D et al (2013) Cardiolipin externalization to the outer mitochondrial membrane acts as an elimination signal for mitophagy in neuronal cells. Nat Cell Biol 15:1197–1205
Deas E, Plun-Favreau H, Gandhi S, Desmond H, Kjaer S, Loh SH, Renton AE, Harvey RJ, Whitworth AJ, Martins LM et al (2011) PINK1 cleavage at position A103 by the mitochondrial protease PARL. Hum Mol Genet 20:867–879
Greene AW, Grenier K, Aguileta MA, Muise S, Farazifard R, Haque ME, McBride HM, Park DS, Fon EA (2012) Mitochondrial processing peptidase regulates PINK1 processing, import and Parkin recruitment. EMBO Rep 13:378–385
Okatsu K, Kimura M, Oka T, Tanaka K, Matsuda N (2015) Unconventional PINK1 localization to the outer membrane of depolarized mitochondria drives Parkin recruitment. J Cell Sci 128:964–978
Kazlauskaite A, Martinez-Torres RJ, Wilkie S, Kumar A, Peltier J, Gonzalez A, Johnson C, Zhang J, Hope AG, Peggie M et al (2015) Binding to serine 65-phosphorylated ubiquitin primes Parkin for optimal PINK1-dependent phosphorylation and activation. EMBO Rep 16:939–954
Narendra D, Tanaka A, Suen DF, Youle RJ (2008) Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol 183:795–803
Khalil B, El Fissi N, Aouane A, Cabirol-Pol MJ, Rival T, Lievens JC (2015) PINK1-induced mitophagy promotes neuroprotection in Huntington’s disease. Cell Death Dis 6:e1617
Wong YC, Holzbaur EL (2014) The regulation of autophagosome dynamics by huntingtin and HAP1 is disrupted by expression of mutant huntingtin, leading to defective cargo degradation. J Neurosci Off J Soc Neurosci 34:1293–1305
Rui YN, Xu Z, Patel B, Chen Z, Chen D, Tito A, David G, Sun Y, Stimming EF, Bellen HJ et al (2015) Huntingtin functions as a scaffold for selective macroautophagy. Nat Cell Biol 17:262–275
Sun N, Yun J, Liu J, Malide D, Liu C, Rovira II, Holmstrom KM, Fergusson MM, Yoo YH, Combs CA et al (2015) Measuring In Vivo Mitophagy. Mol Cell 60:685–696
Kuwana T, Newmeyer DD (2003) Bcl-2-family proteins and the role of mitochondria in apoptosis. Curr Opin Cell Biol 15:691–699
Parsons MJ, Green DR (2010) Mitochondria in cell death. Essays Biochem 47:99–114
Tait SW, Green DR (2012) Mitochondria and cell signalling. J Cell Sci 125:807–815
Culmsee C, Mattson MP (2005) p53 in neuronal apoptosis. Biochem Biophys Res Commun 331:761–777
Duan W, Peng Q, Masuda N, Ford E, Tryggestad E, Ladenheim B, Zhao M, Cadet JL, Wong J, Ross CA (2008) Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington’s disease. Neurobiol Dis 30:312–322
Ju TC, Chen HM, Lin JT, Chang CP, Chang WC, Kang JJ, Sun CP, Tao MH, Tu PH, Chang C et al (2011) Nuclear translocation of AMPK-alpha1 potentiates striatal neurodegeneration in Huntington’s disease. J Cell Biol 194:209–227
Kong PJ, Kil MO, Lee H, Kim SS, Johnson GV, Chun W (2009) Increased expression of Bim contributes to the potentiation of serum deprivation-induced apoptotic cell death in Huntington’s disease knock-in striatal cell line. Neurol Res 31:77–83
Leon R, Bhagavatula N, Ulukpo O, McCollum M, Wei J (2010) BimEL as a possible molecular link between proteasome dysfunction and cell death induced by mutant huntingtin. Eur J Neurosci 31:1915–1925
Sassone J, Colciago C, Marchi P, Ascardi C, Alberti L, Di Pardo A, Zippel R, Sipione S, Silani V, Ciammola A (2010) Mutant Huntingtin induces activation of the Bcl-2/adenovirus E1B 19-kDa interacting protein (BNip3). Cell Death Dis 1:e7
Garcia-Martinez JM, Perez-Navarro E, Xifro X, Canals JM, Diaz-Hernandez M, Trioulier Y, Brouillet E, Lucas JJ, Alberch J (2007) BH3-only proteins Bid and Bim(EL) are differentially involved in neuronal dysfunction in mouse models of Huntington’s disease. J Neurosci Res 85:2756–2769
Hansson O, Castilho RF, Korhonen L, Lindholm D, Bates GP, Brundin P (2001) Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington’s disease is dependent on age and CAG repeat length. J Neurochem 78:694–703
Teles AV, Rosenstock TR, Okuno CS, Lopes GS, Bertoncini CR, Smaili SS (2008) Increase in bax expression and apoptosis are associated in Huntington’s disease progression. Neurosci Lett 438:59–63
Chiang MC, Chen CM, Lee MR, Chen HW, Chen HM, Wu YS, Hung CH, Kang JJ, Chang CP, Chang C et al (2010) Modulation of energy deficiency in Huntington’s disease via activation of the peroxisome proliferator-activated receptor gamma. Hum Mol Genet 19:4043–4058
Zhang Y, Ona VO, Li M, Drozda M, Dubois-Dauphin M, Przedborski S, Ferrante RJ, Friedlander RM (2003) Sequential activation of individual caspases, and of alterations in Bcl-2 proapoptotic signals in a mouse model of Huntington’s disease. J Neurochem 87:1184–1192
Goffredo D, Rigamonti D, Zuccato C, Tartari M, Valenza M, Cattaneo E (2005) Prevention of cytosolic IAPs degradation: a potential pharmacological target in Huntington’s Disease. Pharmacol Res 52:140–150
Rosenstock TR, de Brito OM, Lombardi V, Louros S, Ribeiro M, Almeida S, Ferreira IL, Oliveira CR, Rego AC (2011) FK506 ameliorates cell death features in Huntington’s disease striatal cell models. Neurochem Int 59:600–609
Vis JC, Schipper E, de Boer-van Huizen RT, Verbeek MM, de Waal RM, Wesseling P, ten Donkelaar HJ, Kremer B (2005) Expression pattern of apoptosis-related markers in Huntington’s disease. Acta Neuropathol 109:321–328
Ciammola A, Sassone J, Alberti L, Meola G, Mancinelli E, Russo MA, Squitieri F, Silani V (2006) Increased apoptosis, Huntingtin inclusions and altered differentiation in muscle cell cultures from Huntington’s disease subjects. Cell Death Differ 13:2068–2078
Graham RK, Deng Y, Carroll J, Vaid K, Cowan C, Pouladi MA, Metzler M, Bissada N, Wang L, Faull RL et al (2010) Cleavage at the 586 amino acid caspase-6 site in mutant huntingtin influences caspase-6 activation in vivo. J Neurosci 30:15019–15029
Graham RK, Deng Y, Slow EJ, Haigh B, Bissada N, Lu G, Pearson J, Shehadeh J, Bertram L, Murphy Z et al (2006) Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell 125:1179–1191
Hermel E, Gafni J, Propp SS, Leavitt BR, Wellington CL, Young JE, Hackam AS, Logvinova AV, Peel AL, Chen SF et al (2004) Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington’s disease. Cell Death Differ 11:424–438
Warby SC, Doty CN, Graham RK, Carroll JB, Yang YZ, Singaraja RR, Overall CM, Hayden MR (2008) Activated caspase-6 and caspase-6-cleaved fragments of huntingtin specifically colocalize in the nucleus. Hum Mol Genet 17:2390–2404
Tebbenkamp AT, Green C, Xu G, Denovan-Wright EM, Rising AC, Fromholt SE, Brown HH, Swing D, Mandel RJ, Tessarollo L et al (2011) Transgenic mice expressing caspase-6-derived N-terminal fragments of mutant huntingtin develop neurologic abnormalities with predominant cytoplasmic inclusion pathology composed largely of a smaller proteolytic derivative. Hum Mol Genet 20:2770–2782
Waldron-Roby E, Ratovitski T, Wang X, Jiang M, Watkin E, Arbez N, Graham RK, Hayden MR, Hou Z, Mori S et al (2012) Transgenic mouse model expressing the caspase 6 fragment of mutant huntingtin. J Neurosci 32:183–193
Gafni J, Papanikolaou T, Degiacomo F, Holcomb J, Chen S, Menalled L, Kudwa A, Fitzpatrick J, Miller S, Ramboz S et al (2012) Caspase-6 activity in a BACHD mouse modulates steady-state levels of mutant huntingtin protein but is not necessary for production of a 586 amino acid proteolytic fragment. J Neurosci 32:7454–7465
Landles C, Weiss A, Franklin S, Howland D, Bates G (2012) Caspase-6 does not contribute to the proteolysis of mutant huntingtin in the HdhQ150 knock-in mouse model of Huntington’s disease. PLoS Curr 4, e4fd085bfc9973
Acknowledgements
The authors acknowledge financial support from ‘Fundação para a Ciência e a Tecnologia’ (FCT), Portugal (projects ref. EXPL/BIM-MEC/2220/2013 and Pest-C/SAU/LA0001/2013–2014), co-financed by ‘Programa Operacional Temático Factores de Competividade’ (COMPETE) and supported by the European community fund (FEDER). ACR also acknowledges financial support from ‘Santa Casa da Misericórdia de Lisboa’ (SCML)—Mantero Belard Neuroscience Prize 2013, and ‘Fundação Luso-Americana para o Desenvolvimento’ (FLAD)—Life Science 2020, Portugal. LN holds a Ph.D. fellowship from ‘Fundação para a Ciência e a Tecnologia’ (FCT), Portugal (Reference SFRH/BD/86655/2012). CL was supported by ‘Fundação Luso-Americana para o Desenvolvimento’ (FLAD) Life Science 2020 Postdoctoral Fellowship.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG
About this chapter
Cite this chapter
Carmo, C., Naia, L., Lopes, C., Rego, A.C. (2018). Mitochondrial Dysfunction in Huntington’s Disease. In: Nóbrega, C., Pereira de Almeida, L. (eds) Polyglutamine Disorders. Advances in Experimental Medicine and Biology, vol 1049. Springer, Cham. https://doi.org/10.1007/978-3-319-71779-1_3
Download citation
DOI: https://doi.org/10.1007/978-3-319-71779-1_3
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-71778-4
Online ISBN: 978-3-319-71779-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)